News

Test your knowledge of the AASLD NAFLD Practice Guidance and its clinical application in light of the new MASLD nomenclature.

ONS-5010 missed the pre-specified non-inferiority endpoint set with the FDA, but Outlook Therapeutics plans to resubmit the BLA in Q1 of 2025.

David G. Armstrong, DPM, PhD, and Michael S. Conte, MD discuss Phase 2 results on anatomically directed lower extremity gene therapy for ulcer healing.

In this analysis, egg consumption among pregnant mothers was found to be insufficient for the development of oral tolerance to eggs among infants at 1 year of age.

A new study supports mindfulness-based interventions as a complementary treatment for patients with schizophrenia spectrum disorders.

Fromme describes the importance of risk stratification in AATD and explains the potential utility of noninvasive fibrosis measures for predicting outcomes.

Amgen’s MariTide achieved up to 20% average weight loss at 52 weeks without hitting a plateau in individuals with obesity or overweight.

The investigators of this study noted an association between obesity and conditions such as rosacea, psoriasis, and lichen simplex chronicus.

A study demonstrates many people with treatment-resistant schizophrenia do not comply with nutritional recommendations, which can contribute to increased mortality risk.

The FDA set the Prescription Drug User Fee Act (PDUFA) date for the investigational RNAi therapeutic as March 23, 2025.

In this segment of the latest Lungcast episode, the characteristics of AERD and the concerns of patients were highlighted.

A study showed high-dose antipsychotics and benzodiazepines were linked to an increased mortality risk for those with schizophrenia. High-dose antidepressants lowered the risk.

Hirschfield describes the need for therapies that address itch in PBC and explains what linerixibat, an IBAT inhibitor, may offer for pruritus.

New 52-week LUNA and 4-year OPTIC data demonstrate Ixo-vec’s potential to reduce injection burden, maintain vision, and achieve lifelong benefits for wet AMD.

This study highlighted that both PASI scores and systemic inflammation, assessed using GlycA levels, were linked with cardiovascular disease.

A recent study suggests ketamine can significantly improve symptoms of PTSD and OCD—but this is based on a review of an insufficient number of randomized controlled trials.

Kavish Patidar, DO, explains how socioeconomic status and healthcare delivery impact outcomes in patients with acute kidney injury and cirrhosis.

With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.

FDA grants Rare Pediatric Disease, Fast Track designations to gildeuretinol, aiming to accelerate treatment for Stargardt disease.

In this analysis, the investigators systematically assessed links between the macronutrient profiles of common allergenic foods and corresponding prevalence of food allergy.

A study identified homelessness and minority status as factors that impact clozapine prescription patterns.

In part 2 of this 2-part discussion, hosts discuss ethical considerations and the growing evidence base around euthanasia and medical assistance in dying.

In part 1 of this 2-part discussion, hosts explore the ethical foundation and background of euthanasia and medically-assisted suicide.

Kugelmas reviews findings from a secondary analysis of the phase 3 ELATIVE trial suggesting elafibranor is associated with stable kidney function.

The sNDA was intended to include positive two-year data in the US Prescribing Information for avacincaptad pegol based on the GATHER2 clinical trial.

The supplemental Biologics License Application is supported by the phase 3 ASTRO study of guselkumab SC induction therapy in ulcerative colitis.

Following the publication of the new RLS recommendations, HCPLive spoke with John Winkelman, MD, PhD, chair of the AASM committee that revised the guidelines.

This meta-analysis showed that both secondary closure techniques substantially reduce the risk of hidradenitis suppurativa recurrence compared to primary direct closure.